Literature DB >> 11445792

Intravenous nicardipine for treatment of severe hypertension in children.

J T Flynn1, T A Mottes, P D Brophy, D B Kershaw, W E Smoyer, T E Bunchman.   

Abstract

OBJECTIVE: To examine the effect of intravenous nicardipine in the treatment of children with severe hypertension.
METHODS: The medical records of 29 children (mean age 94 months) treated with intravenous nicardipine were retrospectively reviewed. The mean duration of severe hypertension before nicardipine use was 12.5 hours. Most (74%) patients were receiving other antihypertensive agents before nicardipine.
RESULTS: The initial nicardipine dose was 0.8 +/- 0.3 microg/kg/min (mean +/- SD). The mean effective dose was 1.8 +/- 1.0 microg/kg/min (range, 0.3 to 4.0). Blood pressure control was achieved within 2.7 +/- 2.1 hours after nicardipine was started. Nicardipine treatment produced a 16% reduction in systolic blood pressure, a 23% reduction in diastolic blood pressure, and a 7% increase in heart rate. Nicardipine was effective as a single agent on 26 (84%) of 31 occasions. Adverse effects included tachycardia, flushing, palpitations, and hypotension.
CONCLUSIONS: When administered in the intensive care unit setting with close patient monitoring, intravenous nicardipine effectively lowered blood pressure in children with severe hypertension. Larger prospective studies should be conducted to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445792     DOI: 10.1067/mpd.2001.114030

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  26 in total

Review 1.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Drug treatment of hypertensive crisis in children.

Authors:  Christopher A Thomas
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

3.  Evaluation of the safety and efficacy of metoprolol infusion for children and adolescents with hypertensive crises: a retrospective case series.

Authors:  Rola Saqan; Hanan Thiabat
Journal:  Pediatr Nephrol       Date:  2017-07-21       Impact factor: 3.714

Review 4.  The pediatric cardiology pharmacopeia: 2013 update.

Authors:  Paul Nicholas Severin; Sawsan Awad; Beth Shields; Joan Hoffman; William Bonney; Edmundo Cortez; Rani Ganesan; Aloka Patel; Steve Barnes; Sean Barnes; Shada Al-Anani; Umang Gupta; Yolandee Bell Cheddar; Ismael E Gonzalez; Kiran Mallula; Hani Ghawi; Suhaib Kazmouz; Salwa Gendi; Ra-id Abdulla
Journal:  Pediatr Cardiol       Date:  2012-11-29       Impact factor: 1.655

Review 5.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

Review 6.  Neonatal hypertension: cases, causes, and clinical approach.

Authors:  Michelle C Starr; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2018-05-28       Impact factor: 3.714

Review 7.  Therapy of acute hypertension in hospitalized children and adolescents.

Authors:  Tennille N Webb; Ibrahim F Shatat; Yosuke Miyashita
Journal:  Curr Hypertens Rep       Date:  2014-04       Impact factor: 5.369

8.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

Review 9.  Pharmacologic Control of Blood Pressure in Infants and Children.

Authors:  Joseph D Tobias; Aymen Naguib; Janet Simsic; Catherine D Krawczeski
Journal:  Pediatr Cardiol       Date:  2020-09-11       Impact factor: 1.655

10.  Systemic Hypertension: Management in Children and Adolescents.

Authors:  Craig W. Belsha
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.